GB2287709A - Silylated azetidinone intermediates - Google Patents

Silylated azetidinone intermediates Download PDF

Info

Publication number
GB2287709A
GB2287709A GB9406073A GB9406073A GB2287709A GB 2287709 A GB2287709 A GB 2287709A GB 9406073 A GB9406073 A GB 9406073A GB 9406073 A GB9406073 A GB 9406073A GB 2287709 A GB2287709 A GB 2287709A
Authority
GB
United Kingdom
Prior art keywords
formula
compound
solution
reaction
trialkylsilyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9406073A
Other versions
GB9406073D0 (en
Inventor
Angelo Pecunioso
Chiara Ghiron
Elisabetta Piga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
Glaxo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo SpA filed Critical Glaxo SpA
Priority to GB9406073A priority Critical patent/GB2287709A/en
Publication of GB9406073D0 publication Critical patent/GB9406073D0/en
Publication of GB2287709A publication Critical patent/GB2287709A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • C07F7/1872Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

A process for the preparation of a compound of formula (I) wherein R1 is a trialkylsilyl group and R2 is a hydrogen atom or a trialkylsilyl group <IMAGE> which comprises reacting the azetidinone (II) with the homochiral enol ester (III> <IMAGE> in an aprotic solvent in the presence of a slannic catalyst.n

Description

Chemical Process The present invention relates to an improved process for the preparation of an intermediate useful in the preparation of antibacterial agents.
European Patent Application, publication No. 041 6953A2 describes a novel class of tricyclic antibacterial agents. A particularly preferred compound described and claimed therein is the compound (A)
and salts thereof.
A key intermediate in the synthesis of compound (A) is the methoxy ketone (B).
wherein R1 is a hydroxyl protecting group such as trialkylsilyl group e.g. tbulydimethylsilyl. The present invention provides an improved process for preparing the intermediates of formula (B) with a high degree of enantiomeric purity.
Thus the present invention provides a process for the preparation of compounds of formula (I)
wherein R1 is a trialkylsilyl group and R2 is a hydrogen atom or a trialkysilyl group which comprises reaction of the azetidinone (II) wherein R1 is defined in formula (I) and R2 is a trialkysilyl group
with the homochiral enol ether (III)
wherein R3 is a trialkylsilyl group. The reaction is carried out in an aprotic solvent such as halohydrocarbon e.g. dichloromethane, chlorobenzene or fluorobenzene, acetonitrile or a hydrocarbon e.g. toluene in the presence of a suitable catalyst such as stannic chloride stannic chloride etherate or stannic chloride dimethylsulphide complex and preferably at a temperature within the range -15 to 300 e.g. -15 to 250 and when desired or necessary subsequent conversion of the compound of formula (I) wherein R2 is trialkylsilyl into the corresponding compound of formula (I) wherein R2 is hydrogen.
The trialkylsilyl groups R1, R2 and R3 are preferably tri(C1 4)alkyl groups.
Examples of suitable trialkylsilyl groups include trimethylsilyl and tbutyldimethylsilyl.
A preferred azetidinone (II) for use in the reaction is that wherein R1 is tbutyldimethysilyl and R2 is trimethylsilyl.
A preferred chiral enol ether (III) is that wherein R3 is trimethylsilyl.
The interconversion of a compound of formula (I) wherein R2 is trialkylsilyl into a compound of formula (I) wherein R2 is hydrogen may be carried using conventional methods known for carrying out such reactions. Thus compounds wherein R2 is hydrogen may be prepared from compounds wherein R2 is trimethylsilyl by reaction with acetic acid and tetrabutylammonium fluoride in an aprotic solvent such as tetrahydrofuran or by reaction with trifluoroacetic acid.
The homochiral enol ethers (III) are novel compounds and represent a further aspect of the present invention.
The homochiral enol ether (III) may conveniently be prepared from the homochiral cyclohexanone derivative (IV).
by reaction with an appropriate O-silylating agent. Examples of suitable 0silylating agents include ethyl trimethylsilylacetate or trimethylsilyl trifluoromethylsulphonate.
The reaction of the cyclohexanone derivative (IV) with ethyl trimethylsilylacetate is preferably carried out in the presence of tetrabutylammonium fluoride on silica gel and in a solvent such as an ether e.g. tetrahydrofuran and at a temperature within the range -78-00 e.g. -400.
The reaction of the cyclohexane derivative (IV) with trimethylsilyl trifluoromethylsulphonate is preferably carried out in the presence of a tertiary organic base such as triethylamine and in an aprotic solvent such as dichlormethane.
The cyclohexanone derivative (Ill) may be prepared by oxidation of the homochiral hydroxy ether (V)
using conventional procedures. Thus for example the oxidation may be carried out using oxalyl chloride and dimethylsulphoxide, pyridine/sulphur trioxide, sodium hyprochlorite/2,2,6,6-tetramethyl-1 -piperidinyloxy, N-bromacetamide 1 ,3-dibromo-5,5-dimethylhydantoin or Jones reagent (CrO3/H2SO4). The reaction is conveniently carried out in a solvent, the choice of which will depend upon the oxidants to be used. Thus oxidation using oxalylchloride and dimethylsulphoxide is conveniently carried out in a halohydrocarbon e.g.
dichloromethane and at a temperature within the range -780-500. Oxidation using pyridine and sulphur trioxide is conveniently carried out in a solvent such as an ether e.g. t-butylmethyl ether and in the presence of acetone and a base such as triethylamine or diisopyropylethylamine.
The homochiral hydroxyether (V) is a known compound and may be prepared using known procedures such as those described by . Honig H, Senfer Wassenthal P, Synthesis 1990, 1137-1140 Laumen K et al, J Chem. Soc., Chem. Commun., 1989, 148-150 or Peterson et al, Jorg. Chem, 1988, 53 19031907 or more preferably by the prodedure described herein below in Intermediate 1.
In order that the invention may be more fully understood the following examples are given by way of illustration only.
Intermediate 1 (1 S.2S)-2-methoxycyclohexanol Immobilised Candida antarctica lipase (Novozyme 435;10g) was added to a solution of (+) trans-2-methoxycyclohexanol (50g), vinyl acetate (42ml) and triethylamine (6ml) in cyclohexane (167ml). The mixture was stirred in a stoppered conical flask for 24h at room temperature and then filtered through a number 3 sinter funnel under vacuum. The filter cake was washed with cyclohexane (100ml). The filtrate (350ml) was taken and vigourously extracted with water (4 x 180ml). The combined water extracts (820ml) were back extracted with cyclohexane (200ml). The water layer was taken and sodium chloride (245g to give 5M) added. After dissolution, the salt solution (ca 900ml) was extracted with ethyl acetate (2 x 450ml) and the combined ethyl acetate extracts were reduced in vacuo to afford the title product as a pale yellow oil (17.5g ee > 99%).
Intermediate 2 (2S)-2-methoxycyclohexanone Concentrated sulphuric acid (6.1 ml) was added to a solution of chromium trioxide (7 g) in water (50ml) cooled to 00. An aliquot of this solution (30ml) was added dropwise over a few minutes to a solution of (1 S,2S)-1-methoxy cyclohexanol (1.95 g) in dichloromethane (15ml) cooled to 00. The solution was vigorously stirred at 0 for 1 h and then quenched by addition of of isopropyi alcohol (2.5 ml). The mixture was extracted with dichloromethane (3x50ml); the combined extracts were washed with a saturated solution sodium bicarbonate (30ml), then with brine (50ml) and dried. The mixture was then filtered over celite; the solution was evaporated under reduced pressure at room temperature to give the title compound as a pale yellow liquid ( yield=56%, e.e.=1 00%).
1 H-NMR(400 MHz; CDC13): 3.68(m,1 H);3.40(s,3H); 2.50(m,1 H);2.22 2.18(m,2H);2.0-1 .8(m,2H);1.6(m,3H).
Intermediate 3 (3S.4R)-1 -(tnmethvlsilvl)-4-acetoxy-3((R)-(t- butyldim ethylsilylxoy)ethyl]azetidine-2-one Triethylamine (5.4ml) and trimethylsilylchloride (4.3ml) were added to a solution of (3S,4R)-4-acetoxy-3((R)-(t-butyldimethylsilyloxy)ethyl]-2-azetidi none (7.5g) in dry tetrahydrofuran (60ml) and the mixture stirred at room temperature for 1 hr.
The reaction mixture was filtered twice on a sintered glass filter under nitrogen and the filtrate concentrated under reduced pressure to give the title compound in 99% yield.
Example 1 (3 S)-3-meth oxy-2-trim ethylsiloxycyclohex-1 -ene To a cooled (-300C) solution of triethylamine (8.4ml) in dry dichloromethane (60ml) under nitrogen, trimethylsilyl trifluoromethylsulphonate (10.2ml) was added. (2S)-2-Methoxycyclohexanone (6g) was added, the mixture was stirred at -300C for 2 hours, and hexane (ca. 3 volumes) was then added. The hexane phase was separated from the oil which precipitated out, concentrated under vacuum and the residue was filtered on a short alumina pad eluting with petroleum ether to give the title compound as a colourless oil (5.5g).
e.e + 86% (shift reagent: trisC3-(trifluoroacetyl-d-camphorate)l Eu(lll), CDCI3) [alD 74.60 (nm = 589, c=2.005, 1=10cm, CH2CI2) 1H-NMR (400 MHz; CDC13) 4.97(1H,dd); 3.49(1H,m); 3.40(3H,s); 2.141.84(3H,m); 1.70-1.44(3H,m); 0.20-0.11 (9H,s).
Example 2 (3S.4R)-3-[(R)-1 -(t-butyldimethylsilyloxy)ethyl]-4t(R)-2'-((S)-61m ethoxy-1 - oxocyclohexyl)azetidine-2-one To a solution of intermediate 3 (9.49) and the compound of Example 1 (139) in an hydros dichloromethane (50ml) was added dropwise a preformed solution of stannic chloride etherate (6.1 ml) in dry dichloromethane (80ml) (over 20 mins) keeping the reaction flask in a water bath at room temperature.The bright yellow solution was stirred for an additional 10 mins, poured into a stirred ice-cold saturated solution of sodium hydrogen carbonate (800ml) and diluted with diethyl ether (500ml). The mixture was filtered on a Celite pad and then extracted twice with diethyl ether (2x500ml). The combined organic extracts were washed with brine, then dried over sodium sulphate and evaporated under vacuum. The resulting yellow oil was dissolved in distilled tetrahydrofuran (150ml), then acetic acid (0.9eq.) and tetrabutylammonium fluoride (0.9eq. from 1.1 M soln. in tetrahydrofuran) were added and the reaction stirred under nitrogen for one hour. The reaction was then poured into a saturated solution of sodium hydrogen carbonate (150ml) and extracted with diethyl ether (2x100ml).
The organic layer was washed with ice cold hydrochloride acid (2% soln.), then with a saturated solution of sodium hydrogen carbonate, and finally brine. The organic phase washed and evaporation of the solvent afforded an oil (ca. 1 3g).
The residue was dissolved into acetonitrile (80ml). The white solid which precipitated was filtered off. Acetonitrile (15ml) and water (5ml) were added to the filtrate, which was extracted with cyclohexane (2x15ml). Evaporation of the acetonitrile afforded an oil which was filtered through a silica pad (50g) eluting with petroleum ether (2 1) and then diethyl ether/petroleum ether 1/1(2 1). The elutant was concentrated and the residue crystallised from petroleum ether to give the title compound (2.19). The mother liquors were filtrered on a silica pad, concentrated and the residue crystallized from petroleum ether to give additional 500mg of the title compound.
Example 3 (3S .4R)-3-f(R)-1 -(t-butyldimethylsilyloxy)ethyl]-4[(R )-2'-(S)-6'-methoxy-1 'oxocyclohexyl)azetidin-2-one Tin tetrachloride (0.86ml) was added to dry fluorobenzene (20ml), under a nitrogen atmosphere. The solution was cooled to -6 C, then a solution of intermediate 3 (1.2g) in dry fluorobenzene (14ml) was added over 15 minutes.The mixture was stirred for 5 min at 0 C, then a solution of (-)-3 methoxy-2-tri methylsilyloxycyclohex-1 -ene (1.4ml) in i n dry fluorobenzene (1 4ml) was added over 30 minutes. The reaction was stirred at 0 C for further 7 minutes and then poured into a mixture of Rochelle salt (100ml), saturated sodium hydrogen carbonate solution (100ml) and ethyl acetate (200ml). The mixture was stirred for 20 minutes, then the layers were separated. The aqueous layer was extracted with further ethyl acetate (100ml). The combined organic extracts were washed with brine (50ml), dried (Na2SO4) and concentrated in vacuo to give an oil (1.9g).
This material was dissolved in dichloromethane (24ml) and treated with potassium fluoride (0.29), tetrabutyl ammonium bromide (1.lg) and acetic acid (0.2ml). The suspension was stirred at 23"C for 30 minutes, then a satured sodium hydrogen carbonate solution (50my) was added and the mixture was stirred for 30 minutes. The layers were separated; the organic layer was washed with water (2x50ml), dried (Na2SO4) and concentrated in vacuo to give the crude title compound (1.859) as a white solid.
A portion (1.579) was crystallized from n-hexane to give the title compound as a white solid (0.729).
1H-NMR (CDC13): 5.76 (s, 1H); 4.18 (m, 1H); 3.99 (m,1H); 3.57 (t, 1H); 3.27 (s, 3H); 3.09 (m, 1 H); 2.88 (dd, 1 H); 2.23 (m, 1 H); 2.09(m, 1 H); 1.99 (m, 1 H); 1.771.5 (m, 3H); 1.24 (d, 3H); 0.87 (s, 9H); 0.07 (s, 3H); 0.06 (s, 3H).
Example 4 (3S .4R)-3-[(R)-I -(t-butyidimethylsilyloxy)ethyl]-4ttR)-2'-(S!-6'-methoXv^1 '- oxocyclohexyl)azetidin-2-one To a stirred solution of tin tetrachloride (6.5ml) in dry dichloromethane (80 ml) at 0 C under nitrogen was added dry dimethylsulphide (8.2 ml) over 5 minutes. The resulting solution was stirred for 5 minutes before being allowed to reach room temperature. To the reaction flask was introduced a solution of Intermediate 3 (10g) and Example 1 (16 ml) in dry dichloromethane (100 ml) dropwise over 1 h. The reaction mixture was then stirred for a further 1.5 h before pouring into a stirred mixture of saturated aqueous NaHCO3 (500 ml) and saturated aqueous Rochelle's salt (500 ml) and ethyl acetate (600 ml). After 20 min, the aqueous phase was washed with ethyl acetate (3 x 200 ml) and the combined organic phases were washed with saturated brine (400 ml), dried over an hydros sodium sulphate (2009), filtered and the solvents removed under reduced pressure. The resulting viscous oil was dissolved in ethanol (50 ml) and treated with vegetable charcoal (3.9 g) at reflux for 45 min. After filtration under reduced pressure, the solvent was evaporated to give a crude foam (11 g) which was dissolved in hot n-hexane (20ml), allowed to reach room temperature and seeded with a few crystals of the title compound before standing at 40C for 6 h. The resulting precipitate was filtered washed with cold hexane (3 x 20 ml) and dried under vacuum to afford the title compound (2.8 g) as an off-white solid.
The mother liquors were evaporated to give a foam (8 g) which was dissolved in nhexane (20 ml) and filtered through a pad of silica gel (16 g in a pad 9 cm high).
The pad was then washed with separate aliquots of n-hexane (10 x 50 ml) and then 50 : 1 n-hexane : ethyl acetate (3 x 200 ml). The filtrate fractions collected containing the desired product (TLC) were evaporated to dryness to give title compound as a colourless solid (1.4 g).
1H-NMR(400 MHZ);CDCl3) 5.75(1H sa);4.18(1H m), 3.99(1H m); 3.57(1H t); 3.28(3H s); 3.10(1H m); 2.88(1H dd); 2.24(1H m); 2.09(1H m); 1.99(1H m); 1.71.5(3H m); 1.24(3H d); 0.87(3H s); 0.08 (3H s); 0.06(3H s).

Claims (5)

  1. Claims
    A process for the preparation of a compound of formula (I) wherein R, is a trialkylsilyl group and R2 is a hydrogen atom or a trialkylsilyl group
    which comprises reacting the azetidinone (II) wherein R1 is as defined in formula (I) and R2 is a trialkylsilyl group
    with the homochiral enol ester (III) wherein R3 is a trialkylsilyl group
    in an aprotic solvent and in the presence of a catalyst selected from stannic chloride, stannic chloride etherate or a stannic chloride dimethylsulphide complex, followed when desired or necessary by the subsequent conversion of a compound of formula (I) wherein R2 is trialkylsilyl into the corresponding compound of formula (I) wherein R2 is hydrogen.
  2. 2. A process as claimed in claim 1 wherein the aprotic solvent is a halohydrocarbon.
  3. 3. A process as claimed in claim 1 or claim 2 wherein the reaction is carried out at a temperature within the range -15" to 300.
  4. 4. A process as claimed in any of claims 1 to 3 wherein R1 is a tbutyldimethylsilyl group and R2 and R3 each represent a trimethylsilyl group.
  5. 5. A compound of formula (I), as defined in claim 1 whenever prepared by a process as claimed in any of claims 1 to 4.
GB9406073A 1994-03-26 1994-03-26 Silylated azetidinone intermediates Withdrawn GB2287709A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9406073A GB2287709A (en) 1994-03-26 1994-03-26 Silylated azetidinone intermediates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9406073A GB2287709A (en) 1994-03-26 1994-03-26 Silylated azetidinone intermediates

Publications (2)

Publication Number Publication Date
GB9406073D0 GB9406073D0 (en) 1994-05-18
GB2287709A true GB2287709A (en) 1995-09-27

Family

ID=10752599

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9406073A Withdrawn GB2287709A (en) 1994-03-26 1994-03-26 Silylated azetidinone intermediates

Country Status (1)

Country Link
GB (1) GB2287709A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847989A1 (en) * 1996-12-12 1998-06-17 Takasago International Corporation Process for producing cyclohexylazetidinone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416952A2 (en) * 1989-09-08 1991-03-13 GLAXO S.p.A. 4-(1'-Oxocyclohex-2'-yl)azetidin-2-one derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416952A2 (en) * 1989-09-08 1991-03-13 GLAXO S.p.A. 4-(1'-Oxocyclohex-2'-yl)azetidin-2-one derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.Chem. Soc., Chem. Commun., (4), 441-2, (1994). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847989A1 (en) * 1996-12-12 1998-06-17 Takasago International Corporation Process for producing cyclohexylazetidinone

Also Published As

Publication number Publication date
GB9406073D0 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
EP0752984B1 (en) Process for the preparation of cyclohexyl-azetidinones
AU2006225205B2 (en) Process for the manufacture of organic compounds
EP0008497B1 (en) Beta-lactam-containing compounds, their preparation and pharmaceutical compositions containing them
AU596606B2 (en) Azetidin-2-one derivatives and process for production thereof
US4596677A (en) Anhydropenicillin intermediates
US4645854A (en) Process for preparing HMG-CoA reductase inhibitors with a 3,5-dihydroxypentanoate subunit
Annunziata et al. Stereoselective synthesis of 2-azetidinones as cholesterol-absorption inhibitors
GB2287709A (en) Silylated azetidinone intermediates
EP0164049A2 (en) Process for preparing HMG-CoA reductase inhibtors with a 3,5-dihydroxypentanoate subunit
EP0180189A2 (en) Novel beta-lactams and their production
AU2001293726B2 (en) Process for preparing discodermolide and analogues thereof
US4511509A (en) 3-Alkylidine azetidine compound and their production
EP0389244A1 (en) Process for synthesis of FK-506 C10-C18 intermediates
US4079055A (en) Chemical reduction process
US4767853A (en) Synthesis of 1-(allyloxycarbonyl)-methyl-3-(hydroxyethyl)-4-beta-naphthoxythiocarbonylthio-2-azetidinones and hydroxy protected analogs thereof
JPH06104672B2 (en) Penems production method
EP0282241B1 (en) Beta-lactam compounds and production process thereof
JPH1017561A (en) Allyl alcohols and production method thereof
JP3059475B2 (en) Method for producing 2-azetidinone derivative
US5155228A (en) FK-506 C10-C18 process intermediates
JPH04230360A (en) Heterocyclic derivative
US4948885A (en) Synthesis of azetidinones
US5053502A (en) Anhydro penicillin derivatives
US5191074A (en) β-lactam compounds and production process thereof
JP3471067B2 (en) Method for producing optically active 6- (4-substituted inden-1-yl) -2-methyl-4-hepten-3-ols

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)